3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Lung Neoplasms
2
Breast Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Letrozole
20
Docetaxel
16
Cyclophosphamide
13
Zoledronic Acid
12
exemestane
11
Trastuzumab
11
Anastrozole
11
Paclitaxel
10
Tamoxifen
9
Capecitabine
9
Fulvestrant
8
Epirubicin
8
pegfilgrastim
7
pertuzumab
6
liposomal doxorubicin
6
abemaciclib
6
Saline Solution
6
palbociclib
5
Sodium Chloride
5
Dexmedetomidine
5
Carboplatin
5
Bupivacaine
5
Bevacizumab
5
ribociclib
4
pegylated granulocyte colony-stimulating factor
4
eribulin
4
Tranexamic Acid
4
Standard of Care
4
Pamidronate
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
Isoflurane
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled
NCT00575354
2008-04-21
CSIABTEC
Nanjing Medical University
Phase 4
Completed
500 enrolled